Skip to main content
SpringerLink
Log in

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients

  • Originals
  • Published:
Diabetologia Aims and scope Submit manuscript

An Erratum to this article was published on 01 October 1996

Summary

The effects of troglitazone, a novel thiazolidinedione, in non-insulin-dependent diabetic (NIDDM) patients were studied in a double-blind, parallel-group, placebo-controlled, dose-ranging trial. A total of 330 patients (63% male), mean age 57 years (range 39–72), with two fasting capillary blood glucose values ≥ 7 and ≤ 15 mmol/l (within 2.5 mmol/l of each other) were randomised to treatment with placebo or troglitazone at doses of 200, 400, 600 or 800 mg once daily, or 200 or 400 mg twice daily, for 12 weeks. Prior to the study, treatment had been with diet alone (38% patients) or with oral hypoglycaemic agents which were stopped 3–4 weeks before study treatment started. During treatment, HbA1c tended to rise in patients taking placebo (7.2–8.0%), but remained unchanged with all doses of troglitazone. After 12 weeks of treatment, HbA1c was significantly lower in the troglitazone-treated (mean 7.0–7.4%) compared to the placebo-treated (8.0%) patients (p=0.055 to <0.001), as was fasting serum glucose concentration (troglitazone, 9.3–11.0 mmol/l vs placebo, 12.9 mmol/l, p<0.001). All doses of troglitazone were equally effective. Troglitazone also lowered fasting plasma insulin concentration, by 12–26% compared to placebo (p=0.074 to <0.001). Insulin sensitivity assessed by homeostasis model assessment (HOMA) was greater after 12 weeks of treatment in troglitazone-treated patients (troglitazone, 34.3–42.8% vs placebo, 29.9%, p<0.05). In addition, serum triglyceride and non-esterified fatty acid concentrations were significantly lower and HDL cholesterol higher at troglitazone doses of 600 and 800 mg/day. LDL cholesterol increased at 400 and 600 mg doses only (from 4.3 and 3.9 mmol/l at baseline to 4.8 and 4.5 mmol/l, respectively at 12 weeks, p<0.05), but not at doses of 800 mg once daily or 400 mg twice daily. LDL/HDL ratio did not change during treatment. All doses were well tolerated; incidence of adverse events in troglitazone-treated patients was no higher than in those treated with placebo. However, a tendency to reduced neutrophil counts was observed in patients taking the highest doses of troglitazone. We conclude that troglitazone is effective and well-tolerated and shows potential as a new therapeutic agent for the treatment of NIDDM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

NIDDM:

Non-insulin-dependent diabetes mellitus

HDL:

high density lipoprotein

LDL:

low density lipoprotein

NEFA:

non-esterified fatty acids

HOMA:

homeostasis model assessment

References

  1. De Fronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15: 318–368

    Article  Google Scholar 

  2. Turner RC, Matthews DR, Holman RR, Peto J (1982) Relative contributions of insulin deficiency and insulin resistance in maturity-onset diabetes. Lancet 1: 596–598

    Article  CAS  Google Scholar 

  3. Yki-Jarvinen H (1994) Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 343: 91–95

    Article  CAS  PubMed  Google Scholar 

  4. WHO Study Group (1994) Prevention of diabetes mellitus. WHO Technical Report Series 844. World Health Organisation, Geneva, pp 3–7

    Google Scholar 

  5. Martin BC, Warram JH, Krowlewski AS, Bergman RN, Soeldner JS, Kahn CR (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25 year follow-up study. Lancet 340: 925–929

    Article  CAS  PubMed  Google Scholar 

  6. DeFronzo RA, Ferrannini E (1991) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic cardiovascular disease. Diabetes Care 14: 173–194

    Article  CAS  PubMed  Google Scholar 

  7. Eriksson KF, LindgÄrde F (1991) Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 34: 891–898

    Article  CAS  PubMed  Google Scholar 

  8. Page RCL, Harnden KE, Cook JTE, Turner RC (1992) Can life-styles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabet Med 9: 562–566

    Article  CAS  PubMed  Google Scholar 

  9. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterisation of a new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1549–1558

    Article  CAS  PubMed  Google Scholar 

  10. Hargrove DM, Kreutter DK, Gibbs EM, Stevenson RW (1990) Mechanism of action of thiazolidinedione antidiabetic agents. In: Shaffir E (ed) Frontiers in diabetes research, Vol 3, 1st edn. Smith-Gordon, New York, pp 313–319

    Google Scholar 

  11. Kellerer M, Kroder G, Tippmer S et al. (1994) Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 43: 447–453

    Article  CAS  PubMed  Google Scholar 

  12. Kuzuya T, Iwamoto Y, Kosaka K et al. (1991) A pilot clinical trial of a new oral hypoglycaemic agent CS-045 in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 11: 147–154

    Article  CAS  PubMed  Google Scholar 

  13. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JY (1992) Metabolic effects of a new oral hypoglycaemic agent, CS-045 in NIDDM subjects. Diabetes Care 15: 193–203

    Article  CAS  PubMed  Google Scholar 

  14. Mimura K, Umeda F, Hiramatsu S et al. (1994) Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11: 685–691

    Article  CAS  PubMed  Google Scholar 

  15. Schnek AG, Schroeder WA (1961) The relationship between the minor components of whole normal adult haemoglobin as isolated by chromatography and starch block electrophoresis. J Am Chem Soc 83: 1472–1476

    Article  CAS  Google Scholar 

  16. Soeldner JS, Slone D (1965) Critical variables in the radioimmunoassay of serum insulin using the double antibody technique. Diabetes 14: 771–779

    Article  CAS  PubMed  Google Scholar 

  17. Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548

    Article  CAS  PubMed  Google Scholar 

  18. Friedewald WT, Levy RI, Friedrickson DS (1972) Estimation of concentrations of low density lipoprotein cholesterol in plasma, without the use of ultracentrifugation. Clin Chem 18: 499–502

    CAS  PubMed  Google Scholar 

  19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and Β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419

    Article  CAS  PubMed  Google Scholar 

  20. Fleiss JL (1986) The design and analysis of clinical experiments. Wiley, New York, pp 186–207

    Google Scholar 

  21. Williams G (1994) Management of non-insulin-dependent diabetes mellitus. Lancet 343: 95–100

    Article  CAS  PubMed  Google Scholar 

  22. Gerich JE (1989) Oral hypoglycaemic agents. N Engl J Med 321: 1231–1245

    Article  CAS  PubMed  Google Scholar 

  23. Kosaka K, Kuzuya T, Akanuma Y, Hagura R (1980) Increase in insulin response after treatment of overt maturity-onset diabetes is independent of mode of treatment. Diabetologia 18: 23–28

    Article  CAS  PubMed  Google Scholar 

  24. Randle PJ, Kerbey A, Espinal J (1988) Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metabol Rev 4: 623–638

    Article  CAS  Google Scholar 

  25. Reaven GM (1995) The fourth musketeer — from Alexandre Dumas to Claude Bernard. Diabetologia 38: 3–13

    Article  CAS  PubMed  Google Scholar 

  26. Lehman JM, Moore LB, Smith-Oliver TA et al. (1995) An antidiabetic thiazolidine dione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270(22):12953–12956

    Article  Google Scholar 

  27. Kumar S, Durrington PN, Bhatnagar D, Laing I (1994) Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome. Lancet 343: 1073–1074

    Article  CAS  PubMed  Google Scholar 

  28. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188–1193

    Article  CAS  PubMed  Google Scholar 

  29. Yoshioka T, Aizawa Y, Fujita T et al. (1991) Studies on hindered phenols and analogues. V. Synthesis, identification and anti-diabetic activity of the glucoronide of CS-045. Chem Pharma Bull 39: 2124–2125

    Article  CAS  Google Scholar 

  30. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K (1995) Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8: 316–320

    Article  CAS  PubMed  Google Scholar 

  31. Hermann LS, Schersten B, Bitzen P et al. (1994) Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations. Diabetes Care 17: 1100–1109

    Article  CAS  PubMed  Google Scholar 

  32. Hoffmann J, Spengler M (1994) Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 17: 561–566

    Article  CAS  PubMed  Google Scholar 

  33. UK Prospective Diabetes Study Group (1995) United Kingdom Prospective Diabetes Study Group (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310: 83–88

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, The Royal Infirmary, Oxford Road, M13 9WL, Manchester, UK

    S. Kumar &  A. J. M. Boulton

  2. Medical Department, Odense University Hospital, Odense, Denmark

    H. Beck-Nielsen

  3. Department of Endocrinology, Hospital de L'Antiquaille, Lyon, France

    F. Berthezene

  4. Institute of Medical Pathology, University of Verona, Verona, Italy

    M. Muggeo

  5. Department of Medicine, Sahlgren Institute, Gothenburg, Sweden

    B. Persson

  6. Department of Endocrinology and Metabolism, University Hospital, Zurich, Switzerland

    G. A. Spinas

  7. Medical Division, Glaxo Research and Development, Greenford, UK

    S. Donoghue, S. Lettis & P. Stewart-Long

Authors
  1. S. Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. J. M. Boulton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Beck-Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Berthezene
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Muggeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Persson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. A. Spinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Donoghue
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Lettis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P. Stewart-Long
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Troglitazone study group

Additional information

An Erratum for this chapter can be found at http://dx.doi.org/10.1007/BF02658520

An erratum to this article is available at http://dx.doi.org/10.1007/BF02658520.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, S., Boulton, A.J.M., Beck-Nielsen, H. et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39, 701–709 (1996). https://doi.org/10.1007/BF00418542

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00418542

Keywords

Search

Navigation